KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBT Margin: 2009-2025

Historic EBT Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to 14.42%.

  • Teva Pharmaceutical Industries' EBT Margin rose 2190.00% to 14.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.34%, marking a year-over-year increase of 1642.00%. This contributed to the annual value of -7.76% for FY2024, which is 382.00% down from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' EBT Margin stood at 14.42%, which was up 196.63% from 4.86% recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' EBT Margin ranged from a high of 14.42% in Q3 2025 and a low of -39.38% during Q4 2023.
  • Its 3-year average for EBT Margin is -4.46%, with a median of -5.84% in 2024.
  • In the last 5 years, Teva Pharmaceutical Industries' EBT Margin skyrocketed by 12,192bps in 2021 and then plummeted by 3,899bps in 2022.
  • Teva Pharmaceutical Industries' EBT Margin (Quarterly) stood at -4.27% in 2021, then crashed by 2,624bps to -30.51% in 2022, then plummeted by 887bps to -39.38% in 2023, then surged by 3,354bps to -5.84% in 2024, then soared by 2,190bps to 14.42% in 2025.
  • Its EBT Margin was 14.42% in Q3 2025, compared to 4.86% in Q2 2025 and 7.56% in Q1 2025.